Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Sight Sciences (SGHT) to $5 from $7 and keeps an Equal Weight rating on the shares. Along with Q3 results, Sight flagged some headwinds from both recent and historical reimbursement changes in the MIGS market, notes the firm, which pushed down its 2025 revenue estimate “slightly” as a result.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences price target lowered to $5.50 from $6 at Piper Sandler
- Sight Sciences Reports Modest Growth and Optimistic Outlook
- Sight Sciences backs FY24 revenue view, sees operating expenses down 4%-6%
- Sight Sciences reports Q3 EPS (22c), consensus (21c)
- Sight Sciences Reports Revenue Growth and Leadership Change